In Vitro Antimicrobial Activity of GSQ1530, a New Heteroaromatic Polycyclic Compound

Abstract

GSQ1530 is a compound derived from a newly identified class of antibiotics referred to as heteroaromatic polycyclic (HARP) antibiotics. The aim of this study was to assess the in vitro antimicrobial activity of GSQ1530. By using an NCCLS broth microdilution assay, the activities of GSQ1530 and other antibiotics were coevaluated against 215 clinical isolates. The MICs at which 90% of isolates are inhibited (MIC 90 s) of GSQ1530 for methicillin-susceptible Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) were 2 and 4 g/ml, respectively. The MIC 90 s of GSQ1530 for the streptococci tested were 2 g/ml or less, regardless of their susceptibilities to other antibiotics. The MIC 90 of GSQ1530 for the enterococci tested (including vancomycin-resistant enterococci) was 4 g/ml. No cross-resistance was found between GSQ1530 and other known antibiotics. In a separate assay, GSQ1530 demonstrated excellent activity against vancomycin-intermediate-susceptible staphylococci (MIC 90 , 1 g/ml). The minimal bactericidal concentration test was conducted with 73 clinical isolates; GSQ1530 was cidal against streptococci and staphylococci but static against enterococci. An in vitro killing kinetic study revealed a time-dependent profile, with at least a 3-log reduction of bacterial growth within 6 h after exposure to four times the MICs of GSQ1530 for both S. aureus and Streptococcus pneumoniae. The checkerboard study showed that GSQ1530 had a synergistic interaction with rifampin against MRSA. The test medium was found to have little effect on in vitro antimicrobial potency. The MICs of GSQ1530 for gram-positive cocci were 4-to 32-fold higher in the presence of serum proteins. GSQ1530 has high levels of plasma protein binding (91 and 89% for rat and human plasma, respectively). These preliminary results demonstrate that GSQ1530, a representative compound of our novel HARP antibiotics, has broad-spectrum activity against gram-positive bacteria. This novel class of antibacterial compounds is profiled in vivo to assess the therapeutic potential in humans. Ongoing in vivo studies will assess whether this class of molecules has promising in vivo efficacy and safety profiles.

DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics

“…Despite the issues noted above, the current findings showing that MBX-1066 and MBX-1162 are most potent against DNA and RNA synthesis are consistent with the outcomes of studies of another series of DNA binding antibacterial agents (36). The potent inhibition of DNA and RNA synthesis observed in our studies is most likely to be the consequence of the DNA binding activity of these compounds and actually parallels the relative DNA binding affinities of these compounds (see above).…”

Synthesis and structure–activity relationship of amidine derivatives of 3,4-ethylenedioxythiophene as novel antibacterial agents

“…During the last decade, a series of reports on new classes of compounds that bind to DNA and display potent antibacterial activity were published [12][13][14][15][16]. These antibacterial activity.…”

DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives

“…As a result, they inhibit DNA replication and RNA transcription and consequently kill bacteria. 13 More recently, we described an optimization process in which the influence of the N-and C-terminal units of tetra-heterocyclic compounds on in vitro potency and acute tolerability was investigated. 14 In this study, several new end-terminal substituents were identified; a prototypic structure (1), which has shown in vivo efficacy against a lethal S. aureus infection in the mouse peritonitis model, is shown in Figure 1.…”